Friday, May 27th, 2022


Prevention and Treatment of Substance Use Disorders:
Progress and Prospects for Psychedelic Science

Master of Ceremonies: Dr. Dominique Morisano

8:15 am – 9:00 am

Conference Opening

  • Land acknowledgement: Dr. Brian Rush, CAMH and Dalla Lana School of Public Health, University of Toronto
  • Opening Prayer and Song from Walter Lindstone, Batchewana First Nation Anishinaabe and CAMH (Shkaabe Makwa)
  • Brief Welcome from Planning Committee (Drs. Dominique Morisano, Brian Rush, Monnica Williams, Doris Payer, Sukhpreet Klaire, Thomas Babor, and Mary Bartram)
  • Welcome from host institutions (CAMH, CCSA, MHCC)
  • Remarks by Nathaniel Erskine-Smith, Member of Parliament, Beaches-East York
  • Day 1 Master of Ceremonies: Dr. Dominique Morisano

9:00 am – 9:50 am

Keynote Presentation #1

Historical and recent advances in psychedelic science, neuroscience and clinical contributions to substance use and addictions

  • Dr David Nutt; Imperial College London, Awakn Life Sciences
  • Discussant: Dr Sukhpreet Klaire, University of British Columbia

9:50 am – 10:00 am

Keynote Presentation Q and A

10:00 am – 10:30 am


10:30 am – 11:45 am

Peer-Reviewed Paper presentations

Peer-Reviewed Paper presentations focused on neuroscience/clinical findings in substance use/addictions (4 of 15 minutes)


Watch now


The impact of ineffective placebo control in microdosing trials


  • Dr. Balazs Szigeti, Imperial College London;1
  • Dr. Robin Carhart-Harris, University of California, San Francisco;
  • Dr. David Erritzoe, Imperial College London


Watch now


MDMA Therapy for the Treatment of Alcohol Use Disorder: The Results of the World’s First Study - And Plans for Ongoing Further Research.


  • Dr. Ben Sessa, Imperial College London


Watch Now


Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice


  • Dr. Elizabeth Nielson, Fluence


Watch Now


The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity


  • Peter Bedford, Centre for Addiction and Mental Health;
  • Daniel Hauke, University of Basel;
  • Zheng Wang, Centre for Addiction and Mental Health;
  • Dr. Volker Roth, University of Basel;
  • Monika Nagy-Huber, University of Basel;
  • Friederike Holze, University of Basel;
  • Laura Ley, Departement Biomedizin, University of Basel;
  • Dr. Patrick Vizeli, Departement Biomedizin, University of Basel;
  • Dr. Matthias Liechti, University of Basel;
  • Dr. Stefan Borgward, University of Basel;
  • Dr. Felix Müller, University Psychiatric Clinics Basel;
  • Dr. Andreea Diaconescu, Centre for Addiction and Mental Health

*The presenting author is underlined.

11:45 am – 12:45 pm

Lunch (onsite, included)

12:45 pm – 1:35 pm

Keynote Presentation #2

Traditional medicine, culture and psychedelic science: Healing for substance use and addictions

  • Dr. Anja Loizaga-Velder, Nierika Institute for Intercultural Medicine
  • Discussant: Dr. Olivia Marcus, New York University 

1:35 pm – 1:45 pm

Keynote Presentation Q and A

1:45 pm – 3:15 pm

Peer-Reviewed Paper presentations

Peer-Reviewed Paper Presentations focused on traditional approaches to substance use/addictions (5 of 15 minutes)


Watch Now


Naturalistic Psychedelic use Among Indigenous Peoples to Alleviate Racial Trauma


  • Sara de la Salle, University of Ottawa;
  • Sophia Gran-Ruaz, University of Ottawa;
  • Dr. Dawn Davis, NativeSci;
  • Dr. Monnica Williams, University of Ottawa;
  • Dr. Alan Davis, Ohio State University


Watch Now


Integrating Anthropological Knowledge into Psychedelic Spiritual Care: How Indigenous
Wisdom and Ayahuasca Religions can inform Best Practice


  • Dr. Marc Blainey, Homewood Health Centre


Watch Now


Preliminary results from the Ayahuasca Treatment Outcome Project (ATOP): Takiwasi Center Peru.


  • Dr. Brian Rush, Centre for Addiction and Mental Health, University of Toronto
  • Dr. Olivia Marcus, New York University
  • Sara Garcia, Takiwasi Centre, Peru
  • Dr. Anja Loizaga-Velder, Nierika Institute, National Autonomous University of Mexico, Mexico
  • Gabriel Loewinger, Harvard University School of Public Health
  • Ariane Spitalier, Autonomous University of Barcelona,  Spain
  • Dr. Fernando Mendive, Takiwasi Centre, Peru


Watch Now


Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being


  • Maggie Kiraga;
  • Dr. Natasha Mason, Maastricht University;
  • Dr. Malin Uthaug, Maastricht University;
  • Dr. Kim van Oorsouw, Maastricht University;
  • Dr. Stefan Toennes, University of Frankfurt;
  • Dr. Johannes Ramaekers, Maastricht University;
  • Dr. Kim Kuypers, Maastricht University

3:15 pm – 3:45 pm


3:45 pm – 5:15 pm

Peer-Reviewed Paper presentations

Peer-Reviewed Paper Presentations focused on policy, public health, and regulatory issues in substance use and addictions (5 of 15 minutes)


Watch Now


Psychedelics for addiction treatment: enabling access and protecting innovation and opportunity through preserving the public domain


  • Shahin Shams, Porta Sophia;
  • Dr Sisi Li, Porta Sophia;
  • Amanda Pratt, Holtz Center for Science and Technology Studies;
  • Dr. David Casimir, Casimir Jones S.C.;
  • Dr. Thomas Isenbarger, Casimir Jones S.C.


Watch Now


From Policy to Practice, Practice to Policy (P2P): An Interdisciplinary and Practice Based Approach to Ketamine Assisted Therapy Policy Development in Canada


  • Dr. Anthony Barale, The Ketamine Assisted Therapy Association of Canada;
  • Dr. Ian Mitchell, Royal Inland Hospital;
  • Dr. Joel Kailia, The Ketamine Assisted Therapy Association of Canada;
  • Madison Nobbs, Ketamine Assisted Therapy Association of Canada;
  • Dr. Neil Hanon, Ketamine Assisted Therapy Association of Canada;
  • Dr. Sukh Dhiman, The Ketamine Assisted Therapy Association of Canada


Watch Now


The future of psychedelic therapies in health system stewardship


  • Dr. Kenneth Tupper, University of British Columbia


Watch Now


The Canadian Psychedelic Survey; A Cross-Sectional Survey of Psychedelic Use in Canada


  • Dr. Philippe Lucas, Sabi Mind

5:15 pm – 5:30 pm


5:30 pm - 6:30 pm

Evening Panel

Policy, public health, and regulatory issues: Setting the research agenda for psychedelic-assisted therapies for substance use disorders

What are the steps for developing new treatment pathways for substance use disorders with psychedelic-assisted therapies including key research questions, regulatory issues, risk assessment, potential concerns or benefits, etc.

  • Dr. Ken Tupper, University of British Columbia, Canada
  • Ifetayo Harvey, POC Psychedelic Collective, USA
  • Dr. Gady Zabicky Sirot, Mexican CONADIC National Council on Addictions, Mexico
  • Dr. Ben Sessa, Imperial College London and Awakn Life Sciences, UK
  • Dr. Anja Loizaga-Velder, Nierika Institute for Intercultural Medicine, Mexico
  • Moderator: Dr. Dominique Morisano, University of Toronto/University of Ottawa/CAMH

8:00 pm – 9:30 pm

Networking Social Event

Saturday, May 28th, 2022


Prevention and Treatment of Mental Health Disorders:
Part I: Neuroscience/ Clinical Applications; Traditional Medicine/Cultural Considerations

Master of Ceremonies: Mary Sanders

8:45 am – 9:00 am

Opening Remarks and Working Documentary Sneak Peak: Transcendence produced by A Colorful World and directed by Esteban Serrano

9:00 am - 9:50 am

Keynote Presentation #3

Psychedelics and Racial Justice

  • Dr. Monnica Williams, School of Psychology, University of Ottawa
  • Discussant: Victor Cabral, Fluence and American Psychedelic Practitioners Association

9:50 am – 10:00 am

Keynote Presentation Q and A

10:00 am – 10:45 am

Poster Viewing and Refreshment Break


Poster Title



A Matter of Context: A Comparative Study of Generational Media and its Impact on Psychedelic Policy and Regulations

Michael Kydd


A vision for psychedelic research in Canada

Scott Bernstein


Analysis of the brain’s energy landscape dynamics during psilocybin and escitalopram treatment for depression

Parker Singleton


Ayahuasca Awakening A Guide to Self-Discovery Self-Mastery and Self-Care

Jessica Rochester


Behavioural Investigations of Psilocybin in Animals, A Scoping Review

Kat Dobson


Creating an Intercollegiate Psychedelics Network: Student Empowerment with a Global Reach

Joel Lopez


Does psilocybin change synaptic density in the brains of patients with mild cognitive impairment? A double-blind placebo-controlled study design

Jianmeng Song


Experiences of Psychedelic Use Among Individuals with Psychotic Symptoms

Jade Gallo


Functional connectivity during a personalized trauma audio task is altered after MDMA-assisted psychotherapy in PTSD patients and correlates with recovery

Parker Singleton


Ketamine and psilocybin differentially impact top-down predictions during the mismatch negativity: An EEG Study

Shona Allohverdi


Looking through the doors of perception: the past, present and future of psychedelics to treat addiction

Rayyan Zafar


Mushrooms, madness, media: a content analysis of Canadian news media and how it frames the relationship between psilocybin and violence.

David Kryszajtys


Neural correlates of anti-suiciDal rEsponse to kEtamine in treatment resistant biPolar dePression (DEEPP-Study). Opel Label Pilot Clinical Trial

Yuliya Knyahnytska


Neurobiological Effects of Psilocybin in  Treatment Resistant Bipolar Depression: A Protocol for An Emotional-Processing fMRI Pilot Study

Joshua Rosenblat


Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics

Lily Aleksandrova


Patterns of Hallucinogen Use Prior to First Admission to Inpatient Psychiatry in Ontario, Canada between 2006 and 2020

Judy Castañeda


Pharmacological and Pharmacokinetic Profile of CYB003, a Novel, Orally Active Analog of Psilocybin

Geoff Varty


Point of Departure: Training & the Psychedelic Therapeutic Paradigm

Anne Vallely


Preliminary Evidence that a Reduction in Racial Trauma Symptoms Mediates the Association between Acute Psychedelic Effects and Reduced Alcohol Use among People of Color in the United States and Canada

Angela Haeny


Psilocybin's mechanism of action in the treatment of depression

Brandon Chai


Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian Setting

Elena Argento


Psychedelic use, mental health, and suicidality in Canadian university students

Julia Pei


Research Abuses Against People of Colour in Early Psychedelic Research and Implications for Psychedelic Research, Therapy, and Policy

Dana Strauss


Serotonergic Psychedelic Drugs Dynamically Reconfigure Brain Network Organization

Manesh Girn


The Controlled Substances Act Regulations on Schedule I Researcher Registrations and the Investigation of Hallucinogenic Substances

Theresa Carbonaro


The effect of psilocybin therapy for depression on low-frequency brain activity in response to music

Natalie Ertl


The effects of psilocybin-induced glucocorticoid release on post-acute and delayed anxiolysis in mice



The use of psychedelic substances for smoking cessation: A systematic review

Arina Bogdan


Therapeutic Intent and Caregiver Communication in Psychedelic Medicine

Lucas Standing


Will Psychedelic-Assisted Therapies Benefit from COVID-19 Pharmaceutical Regulatory Modernization?  The Future of ‘Alternative’ Therapies in Canada

Agnieszka Doll

10:45 am – 12:15 pm

Peer-Reviewed Paper presentations

Peer-Reviewed Paper presentations focused on neuroscience/clinical findings (5 of 15 minutes)


Watch Now


Ketamine-Assisted  and Psilocybin-Assisted Therapies, delivered within a Community of Practice Framework: Operations and Outcomes of the Roots to Thrive model


  • Shannon Dames, Vancouver Island University;
  • Pamela Kryskow, Vancouver Island University


Watch Now


The Effects of Psilocybin on Cognitive and Neural Flexibility: The Limits of Excessive Flexing


  • Dr. Manoj Doss, Johns Hopkins University School of Medicine


Watch Now


Psychedelic microdosers report therapeutic motivations and longitudinal improvements in mood, mental health and psychomotor functioning relative to non-microdosing comparators


  • Joseph Rootman, UBC Okanagan;
  • Dr. Pamela Kryskow, Vancouver Island University;
  • Dr. Maggie Kiraga;
  • Paul Stamets;
  • Kalin Harvey, Quantified Citizen;
  • Eesmyal Santos-Brault, Quantified Citizen;
  • Dr. Kim Kuypers, Maastricht University;
  • Dr. Zach Walsh, University of British Columbia – Okanagan



A False Renaissance: The story of the first mainstream psychedelic


  • Dr. Elias Dakwar, Columbia University


Watch Now


Trial of Psilocybin versus Escitalopram for Depression; 6 months follow-up data


  • Dr. David Erritzoe, Imperial College London;
  • Dr. Rosalind Watts, Twelve Trees Integration Ltd;
  • Bruna Giribaldi, Imperial College London;
  • Balazs Szigeti, Imperial College London;
  • Dr. Fernando Rosas, Imperial College London;
  • Dr. David Nutt, Imperial College London;
  • Dr. Robin Carhart-Harris, University of California, San Francisco

12:15 pm – 1:15 pm

Lunch (onsite, included)

1:15 pm – 2:45 pm

Peer-Reviewed Paper presentations

Peer-Reviewed Paper Presentations focused on Traditional approaches (5 of 15 minutes)


Watch Now


Revolution or an endless cycle? The epistemic and ethical concerns of psychedelic psychiatry


  • Dr. Olivia Marcus, New York University


Watch Now


Psychedelic Medicine and Muslim Communities: From Sufism to the Modern Era


  • Dr. Manzarsadat Zareashkezari, University of Ottawa


Watch Now


Exploring experiences and perceptions around purging during Ayahuasca rituals: a qualitative study at a drug rehabilitation center in Peru


  • Svĕt Lustig Vijay, London School of Tropical Hygiene and Medicine;
  • Fabio Friso, Center for the Rehabilitation of Drug Addicts and Research on Traditional Medicines;
  • Dr. Magdalena Harris, Department of Public Health, Environments and Society, London School of Tropical Hygiene and Medicine;
  • Dr. Matteo Politi, Center for the Rehabilitation of Drug Addicts and Research on Traditional Medicines


Watch Now


Culturally-Safe PsychedelicAssisted Psychotherapy: A Foundation for Training Programs


  • Tatiana Sanchez, University of British Columbia - Okanagan;
  • Sarah Daniels, University of British Columbia - Okanagan;
  • Michelle St. Pierre, The University of British Columbia;
  • Joseph Rootman, UBC Okanagan;
  • Christopher Nelson, University of British Columbia - Okanagan;
  • Dr. Zach Walsh, University of British Columbia – Okanagan

2:45 pm – 3:15 pm

Refreshment Break

3:15 pm – 4:35 pm

Keynote Presentation #4

Spirit in Science—Traditional and Indigenous Perspectives on Healing Trauma with Psychedelic Plant Medicines

  • Dr. Joseph Tafur, Modern Spirit and Ocotillo Center for Integrative Medicine, author of Fellowship of the River;
  • Susan Beaulieu, Red Lake Nation Anishinaabe and the University of Minnesota
  • Chief Derek Cook, Bloodvein First Nation (Manitoba, Canada)
  • Rainbow Lopez, Tohono O’odham Nation
  • Christine Diindiisi McCleave, Turtle Mountain Anishinaabe and University of Alaska Fairbanks

4:35 pm – 4:45 pm

Keynote Presentation Q and A

4:45 pm – 5:45 pm

Late Breaking Research Presentations (all topics) (3 x 15 minutes)

All topics (3 of 15 minutes)

Traditional medicine and cultural considerations


Watch Now

What Ayahuasca and Shipibo Plant Medicine Taught Me About Healing the Roots of Racism


  • Chaikuni Witan, NIhue Ras Centro Espirtual

Neuroscience and clinical applications


Watch Now

Ibogaine and Acute Opioid Detoxification


  • Dr. Alberto Sola, Clear Sky Recovery Cancun
  • Hirpal Hundial, Universal Ibogaine

Neuroscience and clinical applications

Watch Now
Treatment response in psilocybin-assisted therapy is predicted by baseline neuroticism and mediated by mystical experience and emotional breakthrough


  • Brandon Weiss, Imperial College
  • David Erritzoe, Imperial College London
  • Robin Carhart-Harris, University of California, San Francisco

5:45 pm - 6:00 pm

Closing Remarks

  • Bia Labate, Chacruna Institute for Psychedelic Plant Medicines (Virtual)

7:30 pm - 9:00 pm

Public Event

Psychedelic-Assisted Therapy - Facts & Fiction featuring some of the world’s top researchers in the field of psychedelic-assisted therapies and medicine

  • Dr. David Nutt, Imperial College London
  • Ifetayo Harvey, POC Psychedelic Collective
  • Dr. Dawn Davis, Native Sci CEO
  • Dr. Monnica Williams – School of Psychology, University of Ottawa
  • Dr. Olivia Marcus – New York University
  • Dr. Rick Doblin – MAPS
  • Moderator: Dr. Brian Rush, CAMH/University of Toronto

Sunday, May 29th, 2022


Prevention and Treatment of Mental Health Disorders:
Part II: Public Health, Policy, and Regulatory Considerations

Master of Ceremonies: Dr. Dominique Morisano

8:30 am – 8:45 am

Opening Remarks and Commentary on Challenges in Conducting Clinical Research with Schedule I Psychedelics: From the 1960s to the Present

  • Dr Katherine Bonson, U.S. Food and Drug Administration (Virtual)

8:45 am – 9:25 am

Keynote Presentation #5
Ketamine-Assisted Psychotherapy in North America: A Review and Commentary

  • Dr. Steven Rosonke, Rainfall Medicine
  • Dr. Devon Christie, Numinus Wellness and UBC Family Medicine 
  • Discussant: Dr. Dominique Morisano

9:25 am – 9:45 am

Keynote Presentation Q and A

9:45 am – 10:30 am

Poster Viewing and Refreshment Break


Poster Title



A New Path for Hope: Therapeutic Potential of 5-MeO-DMT – from Nature, to Synthesis, to Health Equity

Robert Kargbo


A Study Design for a Pragmatic, Open-Label, Phase 2 Study of Psilocybin-Research Intervention with Motivational Enhancement for Substance Use Disorders (PRIME-SUD)"

Lindsay Mackay


Accounting for the Clinical Efficacy of Psychedelic Therapies: How to Reconcile Mysticism and the Scientific Worldview?

Tuomas Pernu


Alcohol use, mental health outcomes, and psychedelic use: do mystical experiences matter?

Tashia Petker


Clinical applications of attachment theory in psychedelic-assisted therapy for substance use disorder

Aaron Cherniak


Computationally defined suicidality subtypes and their differential response to psilocybin vs ketamine therapy

Povilas Karvelis


Design and Rationale for an Open-Label Clinical Trial to Evaluate the Feasibility, Clinical Effects, and Safety of Psilocybin-Assisted Psychotherapy for Treatment- Body Dysmorphic Disorder and Treatment-Resistant Obsessive-Compulsive Disorder.

Nicole Ledwos


Development and Implementation of a Canadian Psilocybin-Assisted Therapy Training Program

Joshua Rosenblat


Entity Encounters on Psychedelics: An Active Inference Account of Spirits, Guides, and Invisible Presences

Jonas Mago


Examining the prevalence and impact of adverse life event re-experiencing during the ceremonial use of ayahuasca

Brandon Weiss


Examining the association between psychedelic use, mental health and the COVID-19 pandemic in young adults who use substances

Christopher Nelson


How the "we" helps heal the "me": psychedelic peer supports and communities of care

Amy Bartlett


Intranasal Ketamine in ECT Non-responders with Treatment Resistant Depression. Open Label Pilot Clinical Trial

Yuliya Knyahnytska


Ketamine for the treatment of mental health and substance use disorders: a comprehensive systematic review

Shannon Golsof


L'induction photonique des états de transe : une alternative efficace et élégante aux substances psychoactives en général

Alexandre Quaranta


Low-Dose Psycholytic Therapy: A Neglected Approach?

Torsten Passie


MDMA-assisted therapy: exploratory data demonstrates potential for chronic pain

Devon Christie


Novel Therapies for First Responders and Military Veterans

Jonathan Hill


Personalized medicine and psychedelics

Olga Chernoloz


Psilocybin as a Treatment for Anorexia Nervosa: Study Protocol and 6-Month Feasibility Update

Hannah Douglass


Psilocybin-assisted psychotherapy for Post-traumatic Stress Disorder in Veterans: a protocol description

Rakesh Jetly


Psychedelic Report Index: A Standardized Tool For Indexing and Tracking Subjective Reports of Psychedelic Associated Experiences

Marcos Ibrahim


Randomized, double-blind, placebo-controlled study assessing the efficacy of microdosed psilocybin on reducing depression and/or anxiety levels in adults.

Olga Chernoloz


Real World Effectiveness of Repeated Ketamine Infusions for Treatment Resistant Mood Disorders

Joshua Rosenblat


Right-Wing Psychedelia: Political Pluripotency and Ideology on Drugs

Brian Pace


Safety and Efficacy of Serotonergic Psychedelic Drugs for the Treatment of Anxiety Disorders and Obsessive-Compulsive Disorder: A Systematic Review

Jamie Hujan


Psychedelic interventions to alleviate psychological suffering at the end of life: Protocol for a scoping review

Sarah Kratina


The Condor and the Eagle: Integrating South and North Indigenous traditions

Michael Chaiton-Murray


The efficacy and tolerability of psilocybin in participants with treatment-resistant depression: a phase 2, randomized feasibility study

Joshua Rosenblat


The Relationship between Classic Psychedelics and Suicidality: A Systematic Review

Nikhita Singhal


Therapeutic Uses of Psychedelics for Eating Disorders and Body Image Disorders: A Narrative Review

Justyne Rodas


TRIP protocol for treatment resistant depression.

Tatiana Zdyb


10:30 am – 12:00pm

Peer-Reviewed Paper presentations

Peer-Reviewed Paper presentations focused on policy, public health, and regulatory issues (5 of 15 minutes)


Watch Now


The Need for Psychedelic-Assisted
Therapy in the Black Community
and the Burdens of its Provision


  • Dr. Sonya Faber, Bioville GmbH;
  • Dr. Darron Smith, The University of Memphis (Virtual)


Watch Now


Entheogens and Psychedelics in
Canada, Proposal for a New Paradigm: A Call for a National Advisory Council


  • Rev Dr. Jessica Rochester, Céu do Montreal;
  • Dr. Anne Vallely, University of Ottawa;
  • Dr. Monnica Williams, University of Ottawa;
  • Dr. Paul Grof, Mood Disorders Centre of Ottawa;
  • Kate Caldwell, Interaction Experience;
  • Dr. Harvey Chang, Jewish General Hospital



Psychedelics and the Commercial Determinants of Health: An Ethics
Case Study Analysis of Psychedelic
Industry-Healthcare Relationships


  • Dr. Daniel Buchman, Centre for Addiction and Mental Health


Watch Now


A grounded theory of online
community members’ self-reported
decision-making logic before their
first use of psychedelic self-treatment for depression and/or anxiety.


  • David Kryszajtys, University of Toronto;
  • Dr. Jacqueline Bender, University Health
  • Dr. Brian Rush, Centre for Addiction and Mental Health;
  • Carol Strike, University of Toronto


Watch Now


From Research to Regulatory Negotiations to Reality


  • Dr. Rick Doblin, MAPS

12:00 pm – 1:00 pm

Lunch (onsite, included)

1:00 pm - 2:30 pm

Panel Presentation

World Regulatory and Policy Discussion: A Pathway Forward

  • Dr. Javier Muniz, U.S. Food and Drug Administration;
  • Dr. Jorge Julio Gonzalez Olvera, Director of Attention Models in Mental Health at the Secretariat of the Mexican Board of Mental Health;
  • Dr. Florence Butlen-Ducuing, European Medicines Agency (Virtual);
  • Drs. Jennifer Pelley and Daniel Keene, Health Canada (Virtual);
  • Moderator: Dr. Doris Payer, Canadian Centre on Substance Use and Addiction

2:30 pm - 3:15 pm

Closing Plenary

Psychedelics in mental health and addiction treatment

  • Dr. Matthew Johnson, Center for Psychedelic and Consciousness Research, Johns Hopkins University

3:15 pm – 3:30 pm

Closing Plenary Q and A

3:30 pm – 4:00 pm

Closing Prayer and Acknowledgements

  • Prayer by Elder Clayton Shirt, Plains Cree/Anishinaabe
  • Closing Remarks and Acknowledgements by R2R2022 Co-Founders Drs. Dominique Morisano (CAMH/University of Toronto/University of Ottawa) and Brian Rush (CAMH/University of Toronto)
Stay up to date with global research efforts.

Webinar series is co-hosted by the Evidence Exchange Network (EENet).

Scroll to Top

This website uses cookies to ensure you get the best experience on our website.